Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Camrelizumab + Irinotecan + GM-CSF for Second-line Treatment in Advanced Colorectal Cancer
NCT04929652Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04929652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929652.